RNA干扰技术专利分析

下载PDF

导出

摘要 RNAi具有非常光明的发展前景。目前,包括默克、阿斯利康、罗氏等制药巨头在内的制药公司及生物技术研发公司对RNAi专利非常重视,专利活动活跃。本文对RNAi专利的审批形势、发展历程、分布态势、未来专利争夺热点及潜在的专利争议等问题进行分析探讨。

作者王磊赵晓宇刁天喜

机构地区军事医学科学院卫生勤务与医学情报研究所

出处《预防医学情报杂志》 CAS 2008年第8期633-636,共4页 Journal of Preventive Medicine Information

基金国家高技术研究发展计划(863计划)(2006AA02Z316)

关键词 RNA干扰生物制药专利

参考文献8

1王迪,齐罗场,王进.高调开发RNA干扰药[N].医药经济报,2007-07-18.
2Charlie Schmidt, Portland, Maine. Negotiating the RNAi patent thicket [J]. Nature Biotechnology, 2007, 25(3) : 273-275.
3Merck's Sirna Deal-Expect More From Big Pharma[ EB/OL]. http: // healthcare, seekingalpha, corn/article./19654.
4Silence-siRNA collaboration with AstraZeneca [ EB/OL ] . http: // www. silence-therapeutics, corn/index, php? option = comcontent&task = view&id =74.
5Roche harnesses Alnylam's RNAi tech in $1B deal [EB/OL]. http: //www. fiercebiotech, com/story/roche-harnesses-alnylam-s-maitech-in-1 b-deal/2007-07-09.
6CytRx in licensing deal with Cold Spring Harbor. [ EB/OL]. http: // goliath, ecnext, com/coms2/gi _ 0199 - 6403677/CytRx-in-licensing- deal-with, html.
7Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi)Research Products Market. [ EB/OL]. http: //www. allbusiness, corn/services/business-services/43045471. html.
8Kylin Therapeutics Licenses an RNAi Delivery Technology from Purdue University [ EB/OL ] Http: //www. genengnews. com/news/bnitew= aspx? name =20083613&taxid =3.

预防医学情报杂志

2008年第8期

内容加载中请稍等...